文献速递脊柱关节炎

银屑病关节炎中TNFi初治与经治患者的停药和换药模式:Corrona登记研究

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
PubMed 文献 · RMD Open · 2019-04-24

经治患者停药时间更短(中位20 vs 27个月),停药(p=0.03)和换药(p<0.01)风险更高,结果可帮助指导PsA后线治疗选择。

要点

  • TNFi经治患者较初治患者停药更早(中位20 vs 27个月)且停药风险更高(p=0.03)。
  • TNFi经治患者换用新生物制剂的比例更高(32.7% vs 19.3%,p<0.01)。
  • 多数停药发生在首次随访前,且停药者基线疾病活动度有更高趋势。

核心结论

  • 在真实世界中,TNFi经治的PsA患者较初治患者更早停药且更频繁换药。

主要发现

  • TNFi初治组75/171例(43.9%)停药,经治组80/147例(54.4%)停药。
  • 初治组33/171例(19.3%)换用新生物制剂,经治组48/147例(32.7%)换药。
  • 经治患者停药时间更短(中位20 vs 27个月),停药风险(p=0.03)和换药风险(p<0.01)均更高。
  • 停药者中,初治组49/75例(65.3%)和经治组59/80例(73.8%)在首次随访前停药,其基线疾病活动度有更高趋势。

临床怎么用

  • 对于PsA患者选择后线治疗时,应考虑到TNFi经治者停药和换药风险更高,需更密切监测疗效与耐受性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine patterns of tumour necrosis factor inhibitor (TNFi) use in TNFi-naive and TNFi-experienced patients with psoriatic arthritis (PsA) in the USA. METHODS: All patients aged ≥18 years with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated a TNFi (index therapy) between March 2013 and January 2017 and had ≥1 follow-up visit were included. Times to and rates of discontinuation/switch of the index TNFi were compared between TNFi-naive and TNFi-experienced cohorts. Patient demographics and disease characteristics at the time of TNFi initiation (baseline) were compared between cohorts and between patients who continued versus discontinued their index TNFi by the first follow-up visit within each cohort. RESULTS: This study included 171 TNFi-naive and 147 TNFi-experienced patients (total follow-up, 579.2 person-years). Overall, 75 of 171 TNFi-naive (43.9%) and 80 of 147 TNFi-experienced (54.4%) patients discontinued their index TNFi; 33 of 171 (19.3%) and 48 of 147 (32.7%), respectively, switched to a new biologic. TNFi-experienced patients had a shorter time to discontinuation (median, 20 vs 27 months) and were more likely to discontinue (p=0.03) or switch (p<0.01) compared with TNFi-naive patients. Among those who discontinued, 49 of 75 TNFi-naive (65.3%) and 59 of 80 TNFi-experienced (73.8%) patients discontinued by the first follow-up visit; such patients showed a trend towards higher baseline disease activity compared with those who continued. CONCLUSIONS: The results of this real-world study can help inform treatment decisions when selecting later lines of therapy for patients with PsA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019. PMID: 31168408. doi:10.1136/rmdopen-2018-000880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。